NEW YORK (
CHANGE IN RATINGS
upgraded at Baird from Neutral to Outperform. $20 price target. Marketing environment is improving, led by financial services.
upgraded at Argus from Sell to Buy. $25 price target. Flight demand should improve as the economy recovers.
rated new Neutral at Goldman. CIE was initiated with a Neutral rating. $18 price target. Have conservative expectations about the company's drilling projects in West Africa.
initiated at Credit Suisse with an Outperform rating and $19 price target. Pure play deep water driller focusing in The U.S. Gulf of Mexico and West Africa. 2010 and 2011 EPS estimates set at negative 51 and 52 cents, respectively.
upgraded at UBS from Neutral to Buy. $80 price target. Business jet market is stable, and the stock is attractively valued.
downgraded at FBR from Market Perform to Underperform. $35 price target. Company should see higher competition from ORLY.
initiated at BofA/Merrill with a Buy rating and $4.25 price target. Hotel REIT that owns 76 hotels mostly in high end metro Northeast markets.
upgraded at Deutsche from Hold to Buy. $113 price target. Despite regulatory risk, stock looks attractive, following the recent pullback.
International Game Tech.
downgraded at Goldman from Buy to Neutral. $23 price target. Stock is up 78% over the past year, and trades at a premium to WMS and Bally.
upgraded at Brean Murray from Hold to Buy. $23 price target. Company can generate material operating leverage and exceed earnings expectations.
upgraded at Thomas Weisel to Overweight from Market Weight as the company should benefit from pickup in IT spending. Price target raised to $22 from $18. 2009 and 2010 EPS estimates set at $1.29 and $1.51, respectively.
downgraded at FBR from Outperform to Market Perform. $7.50 price target. Valuation call, as the stock is trading at 1.2 times expected trough book value.
upgraded at Credit Suisse to Outperform from Neutral as gas inventories are now normal versus oversupplied. Maintain $6 price target. 2009 and 2010 EPS estimates set at -$0.78 and -$0.18, respectively.
upgraded at BofA/Merrill to Buy from Neutral on a recovery in corporate IT spending. Price target raised to $40 from $38.
downgraded at Argus from Hold to Sell. Expect market conditions to move along the bottom, until the second half of 2010.
upgraded at FBR to Outperform. $96 price target. International margins are near a bottom. Estimates also increased.
estimates, target raised at UBS. Shares of SLB now seen reaching $90. Estimates also boosted, to reflect strong oilfield reserve results. Buy rating.
( SOA) upgraded at BB&T to Buy. $15 price target. Company has high leverage to the automotive industry, which is poised for a rebound.
downgraded at BMO to Market Perform. Valuation call, based on a $24 price target.
downgraded at Stifel from Hold to Sell. Valuation call, as the company has the highest P/E ratio in the coverage universe.
upgraded at FBR from Market Perform to Outperform. $28 price target. Believe that regional banks can outperform money center names.
St. Jude Medical
downgraded at Argus from Buy to Hold. Company lowered its long-term earnings guidance.
initiated at Credit Suisse with an Outperform rating and $18 target.
initiated at Barclays with an Overweight rating and $19 price target. TMH is one of the best in class of healthcare services, analysts said. 2009 and 2010 EPS estimates set at $1.00.
downgraded at UBS from Buy to Neutral. $15 price target. See diminished earnings power beyond 2010.
STOCK COMMENTS / EPS CHANGES
estimate boosted at Barclays. BA 2009 EPS estimate raised to $1.35 from $1.20, 2010 maintained at $4.40. Reiterate Overweight rating and $65 price target.
estimates, target increased at FBR. BBT estimates were raised through 2011. Credit deterioration has slowed. Market Perform rating and new $27 price target.
estimates increased at UBS through 2011. See better revenue, driven by credit cards. Sell rating and $21 price target.
estimates changed at Barclays. Barclays 2009 EPS estimate reduced to $1.79 from $2.03, 2010 raised to $2.21 from $2.19. Reiterate Overweight rating and $26 price target.
target estimates cut at BofA/Merrill. ENR price target lowered to $71 from $75 to reflect pricing pressure. 2010 and 2011 EPS estimates reduced to $5.11 and $5.70, respectively. Reiterate Buy rating.
estimate increased at Credit Suisse. Credit Suisse raised F 2009 EPS estimate by 6 cents to -$0.28. 2010 and 2011 maintained at 33 cents and 73 cents, respectively. Neutral rating and $7 price target.
price target tweaked at Barclays. Barclays raised FLR price target by a dollar to $69. 2009 and 2010 EPS estimates maintained at $3.80 and $3.60, respectively. Overweight rating.
estimates, target boosted at Goldman. Shares of GE now seen reaching $21. Estimates also raised, to reflect lower taxes and higher industrial profit. Buy rating.
estimates raised at UBS through 2011. Company seeing higher earnings in Capital Finance. Neutral rating and $17 price target.
numbers boosted at FBR. HBAN now seen reaching $5.50. Estimates also raised, to reflect lower provisions. Outperform rating.
cut from Conviction Sell List at Goldman Sachs. Stock lacks major catalysts, though estimates were also lowered, to reflect lower production rates. $23 price target.
numbers lowered at UBS through 2011. Company will be hurt by higher commodity inflation. Buy rating and new $74 price target.
target, estimates higher at BofA/Merrill. MCD price target increased to $70 from $67. 2010 and 2011 EPS estimate raised to $4.40 and $4.87, respectively. Buy rating.
estimates, target increased at Goldman. MCD estimates were boosted through 2011. Company is seeing better comps sales and margins. Buy rating and new $73 price target.
price target boosted at Barclays to $29 from $27. 2009 and 2010 EPS estimates set at $1.62 and $1.90, respectively. Overweight rating.
estimates increased at Goldman through 2012. Expect Office 2010 and Project Natal to be successful like Windows 7. Buy rating and $35 price target.
National Financial Partners
target, estimates raised at BofA/Merrill. NFP price target from $6 to $8. 2010 and 2011 EPS estimates lifted to $1.75 and $1.80, respectively. Maintain Underperform rating.
target, estimates cut at Credit Suisse. Credit Suisse lowered NVE price target to $13 from $16 as Harry Allen plant going into service. 2009 and 2010 EPS estimates cut to 82 cents and 98 cents, respectively. Maintain Neutral rating.
estimates boosted at Morgan Stanley. SE estimates were increased through 2011. Company recently guided to more stable earnings. Equal-weight rating and $24 price target.
estimates, target lowered at Goldman. Shares of TSO now seen reaching $14. Estimates also cut, to reflect lower refining margins. Neutral rating.
This article was written by a staff member of TheStreet.com.